Alexandra Smart
Critical Care Medicine · Lakewood, CONPI 1184770869
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,874 of the $3,386 with a category attached, or 84.9%. Abiomed accounts for 60.7% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $1,357, 2.1 times the $659 reported in 2019.
Across 66 payments — averaging $51.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Medtronic$318
- Bayer$230
- Inari Medical, Inc.$205
- Merck$113
- United Therapeutics Corporation$100
- plus $365 from 10 others
What the payments were for
- Travel & lodging$49115%
- Food & beverage$2,87485%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 25 | $2,055 |
| Medtronic | 2 | $318 |
| Bayer | 11 | $230 |
| Inari Medical, Inc. | 2 | $205 |
| Merck | 5 | $113 |
| United Therapeutics Corporation | 6 | $100 |
| Abbott | 1 | $78 |
| AstraZeneca | 3 | $60 |
| Boehringer Ingelheim | 2 | $46 |
| Grifols USA, LLC | 2 | $38 |
| Boston Scientific | 1 | $37 |
| Mylan Specialty L.p. | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| GSK | 1 | $17 |
| Novartis | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$715
- COREVALVE EVOLUT R$160
- Micra$158
- FLOWTRIEVER CATHETER, S$126
- CT THROMBECTOMY SYSTEM KIT$126
How this compares
$3,386 in reported general payments places this provider in the 80th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 14 | $178,286 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $88,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $54,510 |
| Spiriva RespimatTiotropium Bromide | 18 | $22,521 |
| Bosentan | 11 | $13,690 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $12,390 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $9,686 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $8,213 |
| EliquisApixaban | 14 | $7,860 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,709 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $2,125 |
| Montelukast Sodium | 22 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $25 | $191,97625 claims |
| Grifols USA, LLCProlastin C | $38 | $88,52011 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $17 | $76,58698 claims |
| Boehringer IngelheimSpiriva Respimat | $46 | $22,52118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Lakewood
- Dominic TitoneLakewood$5K
- Mary ElmasriLakewood$4K
- Kolene BaileyLakewood$2K
- Paula DennenLakewood$1K
- Peter RileyLakewood$985
- Joshua LeeLakewood$597
- Matthew DickinsonLakewood$594
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.